{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:12:12Z","timestamp":1790417532439,"version":"4.1.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0104430","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T17:54:27Z","timestamp":1407866067000},"page":"e104430","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Treatment with the Antipsychotic Agent, Risperidone, Reduces Disease Severity in Experimental Autoimmune Encephalomyelitis"],"prefix":"10.1371","volume":"9","author":[{"given":"David","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarrabeth","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirooz","family":"Zareie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kharkrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahna","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Camille","family":"La Flamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/153537020422900102","article-title":"Multiple sclerosis: etiological mechanisms and future directions","volume":"229","author":"JD Lutton","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"C Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-200519050-00001","article-title":"Primary progressive multiple sclerosis : current and future treatment options","volume":"19","author":"SM Leary","year":"2005","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clineuro.2005.11.018","article-title":"Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment","volume":"108","author":"C Confavreux","year":"2006","journal-title":"Clin Neurol Neurosurg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1352458506072344","article-title":"Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?","volume":"13","author":"PS Sorensen","year":"2007","journal-title":"Mult Scler"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WCO.0b013e328300c70d","article-title":"Multiple sclerosis: new treatment trials and emerging therapeutic targets","volume":"21","author":"T DeAngelis","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"ref7","unstructured":"Macdowell KS, Garcia-Bueno B, Madrigal JL, Parellada M, Arango C, <etal>et al<\/etal>.. (2011) Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol: 1\u201315."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1471-4159.2008.05675.x","article-title":"The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production","volume":"107","author":"LT Zheng","year":"2008","journal-title":"J Neurochem"},{"key":"ref9","first-page":"247","article-title":"Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action","volume":"57","author":"A Basta-Kaim","year":"2006","journal-title":"J Physiol Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0074-7742(06)78012-6","article-title":"Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine","volume":"78","author":"O Guillin","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"J van Os","year":"2009","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia","volume":"52","author":"S Kapur","year":"2001","journal-title":"Annu Rev Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"HY Meltzer","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1566-2772(03)00021-5","article-title":"Atypical antipsychotic drug actions: unitary or multiple mechanisms for &apos;atypicality&quot;?","volume":"3","author":"BL Roth","year":"2003","journal-title":"Clinical Neuroscience Research"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"J Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaut.2006.07.006","article-title":"Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited","volume":"27","author":"RD Strous","year":"2006","journal-title":"J Autoimmun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"S Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pharmthera.2011.06.003","article-title":"Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative\/cognitive symptoms and beyond","volume":"132","author":"U Meyer","year":"2011","journal-title":"Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"L Drzyzga","year":"2006","journal-title":"Brain Behav Immun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0447.1993.tb03331.x","article-title":"T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy","volume":"87","author":"N Muller","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0920-9964(00)00094-3","article-title":"Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor","volume":"54","author":"M Maes","year":"2002","journal-title":"Schizophr Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2007.01.019","article-title":"Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro","volume":"92","author":"T Kato","year":"2007","journal-title":"Schizophr Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","article-title":"Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice","volume":"33","author":"H Sugino","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1084\/jem.20031819","article-title":"Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis","volume":"200","author":"E Bettelli","year":"2004","journal-title":"J Exp Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/icb.2008.99","article-title":"Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis","volume":"87","author":"JB Tierney","year":"2009","journal-title":"Immunol Cell Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1128\/IAI.71.9.4996-5004.2003","article-title":"Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis","volume":"71","author":"AC La Flamme","year":"2003","journal-title":"Infect Immun"},{"key":"ref27","first-page":"607","article-title":"Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages","volume":"232","author":"KP Crume","year":"2007","journal-title":"Exp Biol Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(82)90118-X","article-title":"Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids","volume":"126","author":"LC Green","year":"1982","journal-title":"Anal Biochem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/j.1476-5381.2010.01193.x","article-title":"Dopaminergic mechanisms of reinstatement of MDMA-seeking behaviour in rats","volume":"162","author":"S Schenk","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2006.04.048","article-title":"Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat","volume":"540","author":"DV Naiker","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"S Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2006.04.004","article-title":"Behavioural effects of chronic haloperidol and risperidone treatment in rats","volume":"171","author":"T Karl","year":"2006","journal-title":"Behav Brain Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.ijo.0802928","article-title":"Antipsychotic drug-induced weight gain: development of an animal model","volume":"29","author":"MB Cope","year":"2005","journal-title":"Int J Obes (Lond)"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuint.2003.08.018","article-title":"Early glial responses in murine models of multiple sclerosis","volume":"45","author":"MM Ayers","year":"2004","journal-title":"Neurochem Int"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1471-4159.2008.05435.x","article-title":"Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro","volume":"106","author":"T Kato","year":"2008","journal-title":"J Neurochem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pnpbp.2007.06.031","article-title":"The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma","volume":"32","author":"Q Bian","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0165-5728(02)00280-1","article-title":"Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study","volume":"132","author":"F McKenna","year":"2002","journal-title":"J Neuroimmunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/intimm\/dxp033","article-title":"Dopamine released by dendritic cells polarizes Th2 differentiation","volume":"21","author":"K Nakano","year":"2009","journal-title":"Int Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-5728(02)00435-6","article-title":"Catecholamines in a macrophage cell line","volume":"135","author":"SW Brown","year":"2003","journal-title":"J Neuroimmunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.it.2007.07.005","article-title":"The emergence of neurotransmitters as immune modulators","volume":"28","author":"R Franco","year":"2007","journal-title":"Trends Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2006-01-028423","article-title":"Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine\/paracrine inhibitory functional loop","volume":"109","author":"M Cosentino","year":"2007","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0165-5728(97)00155-0","article-title":"Rat lymphocytes produce and secrete acetylcholine in dependence of differentiation and activation","volume":"81","author":"I Rinner","year":"1998","journal-title":"J Neuroimmunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nature06185","article-title":"Phagocyte-derived catecholamines enhance acute inflammatory injury","volume":"449","author":"MA Flierl","year":"2007","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.4049\/jimmunol.1002475","article-title":"Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis\/SCID mouse chimera model","volume":"186","author":"K Nakano","year":"2011","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2009.07.018","article-title":"Role of dopamine in the physiology of T-cells and dendritic cells","volume":"216","author":"R Pacheco","year":"2009","journal-title":"J Neuroimmunol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbrc.2008.06.012","article-title":"Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis","volume":"373","author":"K Nakano","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-4530(94)90003-5","article-title":"Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis","volume":"19","author":"CD Dijkstra","year":"1994","journal-title":"Psychoneuroendocrinology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(03)00215-5","article-title":"Administration of the 5-hydroxytryptamine(1A) receptor antagonist WAY100635 suppresses acute experimental allergic encephalomyelitis in Lewis rats","volume":"342","author":"M Freire-Garabal","year":"2003","journal-title":"Neurosci Lett"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00213-006-0490-4","article-title":"WAY-100635 is a potent dopamine D4 receptor agonist","volume":"188","author":"BR Chemel","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0165-5728(01)00459-3","article-title":"Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism","volume":"122","author":"G Hasko","year":"2002","journal-title":"J Neuroimmunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.4049\/jimmunol.161.7.3767","article-title":"Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice","volume":"161","author":"EH Tran","year":"1998","journal-title":"J Immunol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.4049\/jimmunol.160.11.5588","article-title":"Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent","volume":"160","author":"JA Martiney","year":"1998","journal-title":"J Immunol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nm1620","article-title":"Type II monocytes modulate T cell-mediated central nervous system autoimmune disease","volume":"13","author":"MS Weber","year":"2007","journal-title":"Nat Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-3083.2011.02575.x","article-title":"Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis","volume":"74","author":"A Toker","year":"2011","journal-title":"Scand J Immunol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jnnp.2009.177733","article-title":"Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis","volume":"81","author":"M Calabrese","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.4049\/jimmunol.157.8.3223","article-title":"IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis","volume":"157","author":"DO Willenborg","year":"1996","journal-title":"J Immunol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.156.1.5","article-title":"Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)","volume":"156","author":"IA Ferber","year":"1996","journal-title":"J Immunol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbi.2010.01.014","article-title":"Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis","volume":"24","author":"AC Murphy","year":"2010","journal-title":"Brain Behav Immun"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/jir.2010.0137","article-title":"Interferon-gamma orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis","volume":"31","author":"N Berghmans","year":"2011","journal-title":"J Interferon Cytokine Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0104430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T22:24:35Z","timestamp":1689459875000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0104430"}},"subtitle":[],"editor":[{"given":"Robyn","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0104430","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]}}}